TCPS 2 Article 2.1 (REB Review Requirement)

Article 2.1 of the Tri-Council Policy Statement: Ethical Conduct for Research Involving Humans (TCPS 2) is the threshold provision that determines whether a proposed project must go before a Research Ethics Board (REB) before it can begin. It states that research involving living human participants, or research involving human biological materials — including embryos, fetuses, fetal tissue, reproductive materials, and stem cells connected to human reproduction — requires REB review and approval before the research commences, and that this approval must be maintained for the duration of the research (TCPS 2, Chapter 2, Article 2.1). Chapter 2 goes on, in Articles 2.2 through 2.4, to describe specific circumstances where other protections apply and full REB review is not required, and to clarify that activities which are not ‘research’ as TCPS 2 defines the term — such as quality assurance, quality improvement, and program evaluation carried out for internal institutional purposes rather than to generate generalizable knowledge — fall outside Article 2.1 entirely.

Who Article 2.1 binds

TCPS 2 is not a statute; it is a joint policy of Canada’s three federal research funding agencies — the Canadian Institutes of Health Research (CIHR), the Natural Sciences and Engineering Research Council (NSERC), and the Social Sciences and Humanities Research Council (SSHRC), collectively the Tri-Agencies. Institutions that wish to remain eligible to administer Tri-Agency funding must sign an institutional agreement committing to apply TCPS 2 to all research involving humans conducted under their auspices, regardless of whether any individual project is itself Tri-Agency-funded. This is why Article 2.1’s REB-review trigger reaches far beyond grant-funded studies in practice: once an institution has signed on, its own researchers, students, and staff are bound by the policy for essentially all qualifying human research conducted at or through that institution.

What triggers REB review under Article 2.1

The operational test has two limbs, either of which is sufficient to trigger review:

• Living human participants — any research in which living individuals are directly involved as participants, whether through intervention, interaction, or the collection of identifiable information about them.
• Human biological materials — research using human biological materials, including embryos, fetuses, fetal tissue, human reproductive materials, and stem cells, even where no living participant is directly interacting with the researcher.

If a project meets either limb and no exception in Articles 2.2-2.4 applies, REB review and approval are mandatory before the work starts, and the REB retains ongoing authority over the study (through mechanisms such as annual renewal and review of amendments) for as long as the research continues.

How this differs from the US Common Rule

TCPS 2 Article 2.1 is frequently described as Canada’s counterpart to the United States’ Common Rule (45 CFR 46), and the two regimes share the same basic architecture — an institutional ethics board reviewing human-subjects research before it proceeds — but they are legally distinct and diverge in important ways:

• Legal status. The Common Rule is a binding federal regulation adopted by U.S. federal agencies, enforced through mechanisms tied to federal funding and, for FDA-regulated research, separately under 21 CFR Parts 50 and 56. TCPS 2 is a funding-agency policy that institutions adopt by agreement, not a statute or regulation — its force comes from the institutional agreement with CIHR, NSERC, and SSHRC rather than from an act of Parliament.
• Trigger test. The Common Rule’s jurisdiction turns on two definitions that must both be met — ‘research’ under 45 CFR 46.102(l) and ‘human subject’ under 45 CFR 46.102(e). TCPS 2 Article 2.1 uses its own, differently worded threshold built around ‘research’ involving living participants or human biological materials, so the two tests do not always classify a given project the same way.
• Institutional reach. Because U.S. institutions typically hold a Federalwide Assurance tied to specific funded activity, Common Rule coverage can be scoped more narrowly to federally funded or federally conducted research at some institutions, whereas a Canadian institution’s TCPS 2 agreement generally commits it to applying the policy across all qualifying human research at that institution.
• Review categories. The Common Rule has formal regulatory categories for exempt and expedited review with defined criteria. TCPS 2 instead directs REBs to apply proportionate review — calibrating the depth of review to the level of risk — as a governing principle rather than a fixed regulatory category scheme.

In practice, a multi-country study running arms in both Canada and the United States needs separate ethics approvals under each regime — REB approval under TCPS 2 for the Canadian arm and IRB approval under the Common Rule (or applicable FDA regulations) for the U.S. arm — because satisfying one does not substitute for the other.

Why this matters for research administration

Article 2.1 is usually the first question a Canadian institution’s ethics office asks about any new project: does this meet the definition of research involving living participants or human biological materials? Getting that classification right matters on both sides — treating a genuine research project as exempt QI work to skip REB review is a research-integrity problem, while over-referring non-research institutional activities to the REB wastes REB capacity and delays legitimate operational work. Research administrators, REB coordinators, and grants offices typically build institutional screening tools directly around the Article 2.1 language to make this initial call consistently.